Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immersive

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

Digging deeper to connect with the powerful force of patient understanding

EphMRA's president Karsten Trautmann advocates a holistic approach to market research

Connected Patients – Adopting a patient-centric approach in emerging markets

The concept of patient centricity and putting the patient at the heart of care is being widely adopted by the healthcare industry – the general consensus being that it’s going...

Research Partnership

- PMLiVE

Pfizer drug gets speedy FDA review for rare heart failure complication

Tafamidis chalked up a comprehensive win in its phase III trials programme

- PMLiVE

bluebird bags breakthrough status for CALD gene therapy

News comes after impressive data from a phase II/III trial

- PMLiVE

Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more

News from the frontline of pharma, biotech and healthcare

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

Research Partnership

Intellus Worldwide Summit 2018

Visit us on stand number 413

Research Partnership

- PMLiVE

FDA looks to regulate digital tools

US regulator adds new components to digital health plan

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

Otsuka finally gets FDA OK for kidney disease drug

Approval at last for rare disease treatment

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links